COMPANY PROFILE

BrainEver

Explore full profile

BrainEver's platform treats neurodegenerative diseases based on Homeoproteins (HPs).

Paris, FranceFounded 2015Biotech & Life Sciences

Valuation $100–500M Latest valuation · 2025

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About BrainEver

Operator of a medical research agency intended to develop drugs for the treatment of neurodegenerative disorders. The company's services specialize in the research and development of novel therapeutics using specific proprietary proteins to treat Parkinson's, amyotrophic lateral sclerosis, and Huntington's diseases, enabling healthcare practitioners to avail of drugs while providing the required treatment efficiently. Keywords: Pharmaceuticals and Biotechnology, Drug Research Center, Drug Research Process, Homeoprotein Administration, Medical Research Agency, Neurodegenerative Disorder, Novel Therapeutics.

Source: Dealroom company data

At a glance

Status: Operational
Founded: 2015
Headquarters: Paris, France
Employees: 25
Open positions: None listed
Dealroom signal: 76.7/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Spinout, EIC, EIC Fund, biotech medtech and e-health, Observatoire Deeptech, Horizon Europe, participations bpifrance, observatoire industrial tech
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Latest news

Press, funding announcements and product moves mentioning BrainEver.

See all news

Funding history

5 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES B✓Equity / VC	Jul 2025	$36M	$145M	EIC Fund · IBionext · Relyens	↗
EARLY VC✓Equity / VC	Mar 2022	$0	—	EIC Fund	—

Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Year	Margin	Margin
2026	—	—
2025	—	—
2024	—	—
2023	—	—
2022	—	—
2021	—	—
2020	—	—

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

BrainEver website traffic

Latest recorded traffic for BrainEver is 600 monthly website visits, down 28.6% over the last three months. BrainEver's team grew 4.2% over the past year.

Latest monthly visits600 3-month web change-28.6% 1-year team growth+4.2%

Monthly website visitsOct 2017–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
LMLattice MedicalLattice Medical develops MATTISSE, a fully degradable 3D printed breast implant for natural, uncomplicated breast restoration	Loos, France	Operational	40	$61M	$189M
URUroMemsDeveloping an active implantable medical device which compensates for sphincter insufficiency	Eybens, France	Operational
QPQubit PharmaceuticalsQuantum physics and AI-driven drug discovery platform	Paris, France	Operational
EVEverZomA key asset to the future health of an ageing population	Paris, France	Operational
TTTreeFrog TherapeuticsStem cell company that will enable millions of patients to access the medical revolution of cell	Pessac, France	Operational
XEXenotheraDeveloping improved immunological treatments using their glyco-humanized antibody platform	Nantes, France	Operational
ATAenitis TechnologiesDeveloping a cell treatment device	Paris, France	Operational
SPStep PharmaDeveloping a new class of immunomodulators for auto-immune disease patients	Paris, France	Operational